In this project, we will extend and rigorously evaluate past investments made by the NIH, ACR, and AHRQ in novel health information technology developed by the project team to: enable the systematic collection and integration of Patient Reported Outcome (PRO) and healthcare provider data in routine clinical practice;make use of this data to facilitate patient-provider interaction around optimal use of rheumatoid arthritis (RA) therapies;integrate this data with information in Electronic Health Record (EHR) systems;and demonstrate benefit for both process and outcomes among patients with RA.
Our specific aims are:
Aim 1 : To refine and integrate a novel approach to the electronic collection and use of PRO data from RA patients to facilitate better patient-provider communication, and achievement of Treat to Target (T2T) goals. We will further pilot-test novel and recently-completed technologies developed by our research team: 1) the RhEumatoid Arthritis Disease activitY (READY) electronic measurement tool that will collect data from patients using multiple existing, validated PRO instruments at physician offices and patients'homes via the Internet and smari:phones (e.g. iPhone);2) a risk communication tool focused on optimal use of biologic agents for RA patients considering changes in therapy;and 3) linked EHR-based data available through the ACR's new national registry, the Rheumatology Informatics System for Effectiveness (RISE). With critical input from many key stakeholders, including patients, we will refine this integrated tool in a variety of clinical practices using commonly available computing devices (e.g. iPad) to create a highly generalizable resource that can be deployed across both community and academic practice settings nationally.
Aim 2 : To conduct a cluster-randomized study to examine the effect of the integrated electronic tool to optimize RA patient care. We will test the hypothesis that RA patients receiving care in the physician practices randomized to receive the intervention tool will attain better RA outcomes as quantified by the proportion of patients in each physicians'practice that have achieved a T2T goal of low disease activity or remission one year after randomization.
Past treat to target studies have important problems with respect to generalizability, physician autonomy and acceptability (at least in the U.S.), and practicality for implementation in routine clinical care. Therefore the proposed study will incorporate the salubrious elements of published treat-to-target trials but will avoid their limitations by employing a practical, real-worid design that emphasizes a patient-centered treatment approach supported by innovative health information technology tools that will be rigorously tested.
|Paulsen, Jesseca A; Ptacek, Travis S; Carter, Stephen J et al. (2017) Gut microbiota composition associated with alterations in cardiorespiratory fitness and psychosocial outcomes among breast cancer survivors. Support Care Cancer 25:1563-1570|
|Curtis, Jeffrey R; Chen, Lang; Greenberg, Jeffrey D et al. (2017) The clinical status and economic savings associated with remission among patients with rheumatoid arthritis: leveraging linked registry and claims data for synergistic insights. Pharmacoepidemiol Drug Saf 26:310-319|
|Curtis, Jeffrey R; Danila, Maria I; Chen, Lang et al. (2016) Risk of Cardiovascular Outcomes among Psoriasis Patients Treated with Biologics and Other Systemic Agents. J Psoriasis Psoriatic Arthritis 1:128-137|
|Stoll, Matthew L; Cron, Randy Q (2016) The microbiota in pediatric rheumatic disease: epiphenomenon or therapeutic target? Curr Opin Rheumatol 28:537-43|
|Yen, Po-Yin; Lara, Barbara; Lopetegui, Marcelo et al. (2016) Usability and Workflow Evaluation of ""RhEumAtic Disease activitY"" (READY). A Mobile Application for Rheumatology Patients and Providers. Appl Clin Inform 7:1007-1024|
|Xie, Fenglong; Yun, Huifeng; Bernatsky, Sasha et al. (2016) Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments. Arthritis Rheumatol 68:2612-2617|
|Stoll, M L; Kumar, R; Lefkowitz, E J et al. (2016) Fecal metabolomics in pediatric spondyloarthritis implicate decreased metabolic diversity and altered tryptophan metabolism as pathogenic factors. Genes Immun 17:400-405|
|Yan, Qi; Weeks, Daniel E; Tiwari, Hemant K et al. (2015) Rare-Variant Kernel Machine Test for Longitudinal Data from Population and Family Samples. Hum Hered 80:126-38|
|Curtis, J R; Yang, S; Chen, L et al. (2015) Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. Arthritis Care Res (Hoboken) 67:1345-53|
|Liu, Nianjun (2015) QTL mapping - Current status and challenges: Comment on ""Mapping complex traits as a dynamic system"" by L. Sun and R. Wu. Phys Life Rev 13:194-5|
Showing the most recent 10 out of 23 publications